GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Inclusion Criteria

• •Age ≥18 years with chronic HCV infection
• •Liver biopsy results ≤ 3 years prior to screening indicating the absence of cirrhosis. Alternatively, a non-invasive procedure conducted within 6 months of screening is permitted in countries where allowed
• •Monoinfection with HCV genotype (GT) 1a or 1b
• •HCV RNA ≥ 104 IU/mL at screening
• •Prior treatment and adherence with one course of pegylated interferon alfa and RBV
• •The subject's medical records must include sufficient detail of prior treatment with pegylated interferon alfa and RBV (start/stop dates and viral response) to allow for categorization of prior response as either null, partial, breakthrough or relapse.
• •Body mass index (BMI) 18-40 kg/m2 inclusive
• •Screening ECG without clinically significant abnormalities and with QTcF interval (QT corrected using Fridericia's formula)
• •≤ 450 msec for males and ≤ 470 msec for females.
• •Agree to use two forms of highly effective contraception for the duration of the study and for 7 months after the last dose of study medication. Females of childbearing potential must have a negative pregnancy test at screening and baseline.